These data support the concept that serum ALPL may reflect benign osteoblast production in reaction to prostate cancer osteoblastic bone metastases, and that radium-223 reduces this osteoblast production of ALPL, leading to improved clinical outcomes. This evidence concerns the gene ALPL and Familial prostate cancer.